Navigation Links
Avanir Pharmaceuticals Announces Presentation of Positive Early Results from PRISM II Study
Date:7/16/2014

lly consistent with that observed in other trials of NUEDEXTA. 

About PRISM II
The objectives of the study are to evaluate the safety, tolerability, and effectiveness of NUEDEXTA capsules containing 20 mg dextromethorphan (DM) and 10 mg quinidine (Q) for treatment of PBA in patients with prevalent neurological conditions including Alzheimer's disease/dementia, stroke and traumatic brain injury over a 12 week period.

PRISM II is a nationwide, open-label, multicenter, 12-week study enrolling up to approximately 450 patients at approximately 100 study centers. Eligible patients are aged >18 years with a clinical diagnosis of PBA and baseline score >13 on the Center for Neurologic Study-Lability Scale (CNS-LS). Patients with TBI due to a penetrating head injury are excluded. Patients are treated with NUEDEXTA mg twice daily. The primary endpoint is change from baseline in scores measured by the CNS-LS, a PBA rating instrument originally validated in patients with PBA secondary to ALS and MS. Determination of effectiveness is based on a comparison of CNS-LS change in PRISM II with results of previous phase III studies. Additional outcomes measures include: number of weekly PBA episodes (laughing and/or crying); Mini-Mental State Examination; quality of life; Clinician and Patient Global Impression of Change (CGIC; PGIC); patients' satisfaction with treatment; Patient Health Questionnaire (PHQ-9) (to evaluate mood symptoms), and the Neurobehavioral Functioning Inventory for TBI patients. Safety measures include monitoring of adverse events, concomitant medication usage, and vital signs.

Poster Presentation Details:
Title: PRISM II: An Open-Label Study to Assess the Safety, Tolerability, and Effectiveness of Dextromethorphan 20 mg/Quinidine 10 mg (NUEDEXTA) in Pseudobulbar Affect  (PBA) Secondary to Dementia, Stroke, or Traumatic Brain Injury (TBI): Early Results of the Alzheimer's Disease/Dementia Cohort'/>"/>

SOURCE Avanir Pharmaceuticals, Inc.
Copyright©2014 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7

Related medicine technology :

1. Avanir Pharmaceuticals Pre-announces Preliminary Fiscal 2014 First Quarter Financial Information
2. Avanir Pharmaceuticals to Present at J.P. Morgan 32nd Annual Healthcare Conference
3. Quarterly Dividends, Clinical Trial Results, Dental Exhibition Updates, and Upcoming Presentation Schedules - Research Report Quest Diagnostics, Avanir, Sirona, Ligand and Genomic Health
4. Avanir Pharmaceuticals Reports Fiscal 2013 Fourth Quarter Financial and Year-End Business Results
5. Avanir Pharmaceuticals Announces Results for Phase II PRIME Study
6. Preliminary Financial Results, Quarterly Reports and Upcoming Conference Schedules - Research Report on Avanir, BioScrip, Chemed, Foundation Medicine, and Antares
7. Avanir Pharmaceuticals Pre-Announces Preliminary Fiscal 2013 Year End Financial Information
8. Avanir Pharmaceuticals to Host Investor Day on October 29, 2013
9. Avanir Pharmaceuticals Announces Enrollment of First Patient in Study of AVP-923 for the Treatment of Levodopa Induced Dyskinesia in Parkinsons Disease
10. Avanir Pharmaceuticals Announces Publication of AVP-825 Pharmacokinetic Data in Journal "Headache"
11. Avanir Pharmaceuticals Announces Settlement of NUEDEXTA Patent Litigation with Wockhardt
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:8/22/2014)... Calif. , Aug. 22, 2014  WaferGen Bio-systems, ... underwritten public offering of units of common stock and ... gross proceeds of $20 million, prior to deducting underwriting ... Company.  The shares and warrants are immediately separable and ... are expected to begin trading on The NASDAQ Stock ...
(Date:8/21/2014)... 21, 2014   Memorial Hermann Health System and ... today announced a new partnership to provide a new level ... care centers in the greater Houston ... become the exclusive provider of professional breast radiology services for ... Memorial City, The Woodlands , Northeast, Southwest ...
(Date:8/21/2014)... Nektar Therapeutics (NASDAQ: NKTR ... results from its Phase 3 pivotal clinical trial ... factor VIII (rFVIII) treatment for hemophilia A based ... primary endpoint in reducing annualized bleed rates (ABR) ... arm. Top-line results from the prospective, ...
Breaking Medicine Technology:WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 2WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 3WaferGen Bio-Systems Announces Pricing of $20 Million Underwritten Offering and Uplisting to NASDAQ 4Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 2Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 3Memorial Hermann, MD Anderson join forces to provide enhanced breast imaging services throughout the Greater Houston Region 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 2Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 3Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 4Baxter Announces Positive Top-Line Results from Its Phase 3 Study of BAX 855, Extended Half-Life Recombinant FVIII for Hemophilia A Patients 5
(Date:8/23/2014)... New York, New York (PRWEB) August 23, 2014 ... ( http://www.consumerinjurylawyers.com/wright-conserve-hip-replacement.html ) filed on behalf of ... in the Conserve hip replacement line continue to ... District of Georgia, Bernstein Liebhard LLP reports. According ... has established a bellwether trial program that would ...
(Date:8/23/2014)... NY (PRWEB) August 23, 2014 On ... reported on a data breach suffered by Community ... saw the compromise of 4.5 million records containing Personally ... security numbers. According to Mandiant, who was engaged to ... from an advanced group of cyber attackers based ...
(Date:8/23/2014)... The MPWMD Board of Directors voted on Monday, August 18th ... of water for commercial and industrial properties. This was ... Archworks, LLC in Carmel, California. , This is a ... district in the State of California has approved this technology ... this time can now be used as a sole source ...
(Date:8/23/2014)... Pixel Film Studios, a leader of Final Cut ... ProIntro Vol.3, a customizable title tool for FCPX ... by dragging ProIntro Vol.3 in their timeline" says Christina Austin, ... time saver and i think our users will agree" , ... titles made with Final Cut Pro X users in mind. ...
(Date:8/23/2014)... Dealing with a drug or alcohol substance abuse is never ... child. Adolescent addiction has been an important issue among young ... helpline is now providing a valuable resource for teenage ... addiction recovery center. , The Troubled Teens Atlanta helpline was ... By calling (404) 975-2762, parents and their teens can speak ...
Breaking Medicine News(10 mins):Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 2Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 3Health News:Wright Conserve Hip Lawsuits Move Forward, as Federal Court Issues Order Pertaining to Bellwether Trials, Bernstein Liebhard LLP Reports 4Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 2Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 3Health News:This Time Prominent Hospital Group Falls Prey to Hackers Believed to be Based in China 4Health News:Historical Moment in the Monterey Peninsula, Brings Drought Relief Solution to California, with the Help of EcoloBlue and AWG Technology 2Health News:A new plugin was announced today, ProIntro Vol.3 from Pixel Film Studios for Final Cut Pro X 2Health News:Atlanta’s New Troubled Teen Helpline Is Making a Difference in the Community 2
... cancer are at higher risk of developing diabetes or diabetes ... block the production or action of male hormones that can ... new study on the second-most common cancer in men are ... in Boston. "These patients may benefit from counseling, screening ...
... (Hamilton, ON) June 4, 2011 - Additional radiation treatment ... recurring in women with early breast cancer who have ... new study found. The results will be presented Monday, ... Society of Clinical Oncology. "These results are ...
... a lot of sugar to stay alive. In fact, where normal, ... of oxygen, cancerous cells use virtually no oxygen and a lot ... now, reporting in the May 27 issue of Cell , ... that this so-called Warburg effect is controlled. "It turns ...
... -- ASCO Abstract #10504. Contrary to what many oncologists had ... reduce the effectiveness of the breast cancer drug Herceptin, according ... North Central Cancer Research Group (NCCTG) investigators. The study, ... NCCTG N9831 clinical trial, found that patients with HER2-positive breast ...
... is the most lethal type of skin cancer, the results of ... immune-boosting drug Interleukin-2 can improve response rate and progression-free survival. ... June 2 issue of New England Journal of Medicine . ... one of the first in all cancers to show clinical benefit ...
... Amanda Gardner HealthDay Reporter , THURSDAY, June ... used to treat high blood pressure doesn,t boost the ... health authorities announced Thursday. The drugs are known ... telmisartan (Micardis), losartan (Cozaar), valsartan (Diovan) and candesartan (Atacand). ...
Cached Medicine News:Health News:Hormone deprivation therapy for prostate cancer may raise diabetes risk 2Health News:Breast cancer surgery patients benefit from adding radiation therapy 2Health News:Understanding cancer energetics 2Health News:Mayo Clinic, NCCTG find no tie between PTEN and response to breast cancer drug 2Health News:Vaccine first to show improved survival rates for metastatic melanoma 2Health News:Vaccine first to show improved survival rates for metastatic melanoma 3Health News:Popular Blood Pressure Meds Not Linked to Cancer, FDA Says 2
Spoon end periosteal, polished finish, designed for large mucoperiosteal flaps....
Love-Adson periosteal elevator, semi sharp, blade width 3/16" (5 mm), length 6 1/2" (165 mm)....
Key periosteal elevators, blade width 1" (25 mm), total length 7 1/2" (191 mm)....
Hoen periosteal elevators, No.3, blade width 3/4" (20 mm), total length 7 1/2" (191 mm)....
Medicine Products: